Nitric oxide (NO) is arguably the most important signaling molecule in human physiology. Its discovery earned the 1998 Nobel Prize in Physiology or Medicine for Robert Furchgott, Louis Ignarro, and Ferid Murad. Science magazine named it "Molecule of the Year" in 1992. And one of the primary mechanisms by which photobiomodulation produces therapeutic effects is by triggering the release of nitric oxide from mitochondria — a process that simultaneously restores cellular energy production and improves local blood flow. Understanding this dual mechanism explains many of red light therapy's most clinically significant benefits.
Nitric Oxide: Biology's Master Regulator
Nitric oxide is a simple gas molecule — one nitrogen atom bonded to one oxygen atom (NO). Despite this simplicity, it serves as a critical signaling molecule in virtually every organ system.
| Biological System | NO Function | Clinical Relevance |
|---|---|---|
| Cardiovascular | Vasodilation (relaxes blood vessel walls) | Blood pressure regulation, blood flow, cardiovascular health |
| Immune | Antimicrobial defense, macrophage activation | Pathogen killing, immune signaling |
| Nervous | Neurotransmission, synaptic plasticity | Memory formation, neural communication |
| Mitochondrial | Regulates cytochrome c oxidase (Complex IV) | Modulates cellular energy production |
| Reproductive | Smooth muscle relaxation in reproductive organs | Erectile function (Viagra works via NO pathway) |
| Gastrointestinal | Smooth muscle relaxation, gut motility | Digestive function, gut blood flow |
| Respiratory | Bronchodilation, pulmonary vasodilation | Airflow regulation, gas exchange |
How the Body Produces NO Naturally
The body has three primary nitric oxide synthase (NOS) enzymes that convert L-arginine to NO:
- Endothelial NOS (eNOS): Expressed in blood vessel walls. Produces sustained, low levels of NO for vasodilation. Activated by shear stress (blood flow) and acetylcholine. This is the primary enzyme responsible for cardiovascular NO production
- Neuronal NOS (nNOS): Found in neurons and skeletal muscle. Produces NO for neurotransmission and muscle contraction regulation. Activated by calcium influx during neural activity
- Inducible NOS (iNOS): Expressed in immune cells (macrophages, neutrophils). Produces large amounts of NO for antimicrobial defense. Activated by inflammatory signals (cytokines, bacterial products). Can produce damaging levels of NO during chronic inflammation
Additionally, the "nitrate-nitrite-NO" pathway converts dietary nitrates (from vegetables like beets, spinach, and arugula) into NO through bacterial reduction in the mouth and chemical reduction in acidic conditions.
What makes photobiomodulation unique is that it releases pre-formed NO from a fourth source — mitochondrial stores — through a mechanism entirely distinct from enzymatic synthesis.
The Photodissociation Mechanism: How Light Releases NO
The relationship between nitric oxide and cytochrome c oxidase (CCO) is the key to understanding PBM's NO-mediated effects.
NO as a Mitochondrial Brake
Under normal conditions, NO reversibly binds to the CuB center of cytochrome c oxidase, the terminal enzyme in the electron transport chain. This binding competes with oxygen (O₂) for the same active site. When NO occupies the site, oxygen cannot bind, and electron transport slows or stops.
Brown and Cooper (1994, FEBS Letters) first characterized this inhibition, showing that physiological concentrations of NO (10-100 nM) reduce CCO activity by 30-70%. This serves as an important regulatory mechanism — cells use NO to modulate energy production based on metabolic need and oxygen availability.
However, under pathological conditions — chronic inflammation, tissue damage, ischemia-reperfusion injury, or metabolic dysfunction — excessive NO binding can trap cytochrome c oxidase in an inhibited state, creating an "energy crisis" where cells cannot produce adequate ATP despite having sufficient nutrients and oxygen.
The Light-Triggered Release
Karu et al. (2005, Lasers in Surgery and Medicine, PMID:15739174) showed that low-power laser effects on cells can be mediated by nitric oxide acting at cytochrome c oxidase. That evidence was indirect: added NO donors abolished the light-induced effect in HeLa cells, and no release of NO from the CuB center was observed. The photodissociation sequence below is a leading hypothesis, not a demonstrated process (Hamblin 2018, PMID:29164625):
- Photons in the 600-900nm range are absorbed by the metal centers of CCO
- The absorbed energy weakens and breaks the NO-CuB bond
- Free NO diffuses out of the mitochondria into the cytoplasm
- NO continues diffusing through cell membranes into surrounding tissue and blood vessels
- With NO displaced, oxygen binds to CCO, restoring normal electron transport
- ATP production resumes at full capacity
This process is remarkably fast — measurable NO release occurs within seconds of light exposure (Shiva and Gladwin, 2009, Journal of Molecular Medicine). And it produces a unique "dual benefit" that distinguishes PBM from all other vasodilatory interventions.
The Dual Benefit: Why PBM-Derived NO Is Special
Most vasodilatory interventions (nitroglycerin, exercise, dietary nitrates) increase NO availability through one pathway. Photobiomodulation uniquely produces two simultaneous benefits from a single event.
| Benefit | Mechanism | Effect | Onset |
|---|---|---|---|
| Benefit 1: Restored cellular energy | Removing NO from CCO unblocks electron transport | ATP production increases 20-70% | Seconds to minutes |
| Benefit 2: Improved circulation | Released NO diffuses to blood vessels, activating guanylate cyclase | Vasodilation, increased blood flow 20-40% | Minutes (peaks at 20-30 min) |
No medication produces both of these effects simultaneously. Nitroglycerin provides vasodilation but doesn't improve mitochondrial function. ATP-boosting supplements (CoQ10, creatine) support energy production but don't improve circulation. PBM's dual mechanism is pharmacologically unique.
The NO Signaling Cascade in Blood Vessels
Once released from mitochondria, NO diffuses rapidly (half-life of ~5 seconds in tissue, but it diffuses freely through cell membranes). When it reaches smooth muscle cells surrounding blood vessels, it activates the following cascade:
- NO binds to soluble guanylate cyclase (sGC) in smooth muscle cells
- sGC converts GTP to cyclic GMP (cGMP)
- cGMP activates protein kinase G (PKG)
- PKG reduces intracellular calcium levels
- Lower calcium causes smooth muscle relaxation
- Blood vessel diameter increases (vasodilation)
- Blood flow increases proportionally to the fourth power of vessel radius (Poiseuille's law)
That last point is critical: a modest 10% increase in vessel diameter produces a 46% increase in blood flow (by Poiseuille's law, flow ∝ r⁴). Even small vasodilatory effects translate to substantial circulation improvements.
Measured Circulation Effects of PBM
Several studies are routinely cited as measuring blood flow changes after photobiomodulation. Read against the source papers, they measure different things in different species, and only one of them measured blood flow in humans.
| Study | Measurement Method | Wavelength | What Was Actually Found | Duration / Caveat |
|---|---|---|---|---|
| Samoilova et al. 2008, PMID:18922087 | High-frequency ultrasound Doppler, 42 healthy volunteers | Polychromatic visible light, 385-750nm | Skin blood flow +32% at 2 min and +45% at 20 min; a nitric oxide synthase inhibitor at the site blocked the effect | Returned to baseline by 90 min |
| Mitchell & Mack 2013, PMID:23334615 | Nitrite and nitrate assay in venous blood draining the treated forearm, 15 healthy adults | 890nm | Venous NO metabolites rose at 1, 5 and 15 min. This trial measured NO release; blood flow was never measured | Peaked at 5 min, then waned |
| Maegawa et al. 2000, PMID:11126437 | Intravital microscopy with dual-slit photometry, rat mesentery | 830nm | Dilation of the irradiated arterioles with increased arteriolar blood flow; no percentage change is reported | Animal study; duration not reported |
| Ihsan 2005, PMID:15954817 | Histopathology and HPLC, 34 rabbits with surgically ligated femoral artery | 904nm | Increased collateral vessel proliferation and capillary diameter; blood flow was not measured | Peaked at 12-16 h; animal surgical-ischaemia model, not human blood flow |
| Leal-Junior et al. 2010, PMID:20436237 | Performance and post-exercise biochemical markers, 9 volleyball players | 810nm | Pre-exercise treatment raised biceps repetitions 14.5% and time to exhaustion 8.0%, with lower post-exercise lactate, creatine kinase and CRP. A recovery marker, not a blood flow measure | Single session; blood flow was not measured |
Read together, these studies do not support a single blood flow figure. Only Samoilova 2008 measured blood flow in humans, and it used polychromatic visible light rather than a red or near-infrared panel: skin blood flow rose 32% at 2 minutes and 45% at 20 minutes, then returned to baseline by 90 minutes. The others are an animal arteriole study, an animal surgical-ischaemia model, a trial that measured nitric oxide rather than flow, and an exercise-recovery trial. The widely repeated claim that PBM raises local blood flow by 20-44% is not supported by these sources, and none of them compared the effect with exercise.
Tissue-Specific Circulation Benefits
Wound Healing: Oxygen and Nutrient Delivery
Wound healing is critically dependent on adequate blood supply. Chronic wounds (diabetic ulcers, venous stasis ulcers, pressure injuries) often persist specifically because of inadequate local circulation that cannot deliver the oxygen, nutrients, and immune cells needed for repair.
PBM-derived NO release improves wound circulation through:
- Vasodilation of existing blood vessels in the wound bed and surrounding tissue
- Enhanced angiogenesis (new blood vessel formation) — NO is a potent angiogenic signal
- Improved oxygen diffusion to wound tissue (critical for collagen synthesis, which requires oxygen for proline and lysine hydroxylation)
- Enhanced delivery of growth factors and immune cells to the wound site
Dungel et al. (2014, Lasers in Surgery and Medicine, PMID:25363448) found that both blue (470nm) and red (629nm) LED increased sub-epidermal and intramuscular angiogenesis, improved perfusion and reduced necrosis in an ischaemia-disturbed rat abdominal flap. That study did not test NO dependence — there was no NO-scavenger arm, and the authors reported improved healing irrespective of wavelength. No published study has shown that blocking NO abolishes the wound healing effect of PBM, so NO remains a proposed mediator here rather than a demonstrated one.
Muscle Recovery: Metabolic Waste Clearance
Post-exercise muscle soreness and delayed recovery are partly caused by accumulated metabolic byproducts: lactate, hydrogen ions, reactive oxygen species, and pro-inflammatory cytokines. Efficient clearance of these waste products depends on adequate blood flow through the muscle.
NO-mediated vasodilation following PBM enhances:
- Lactate clearance (faster conversion to glucose in the liver via the Cori cycle)
- Hydrogen ion buffering (improved CO₂ transport to lungs)
- Inflammatory mediator removal (dilution and transport to lymphatic system)
- Oxygen delivery for aerobic repair processes
- Nutrient delivery for muscle protein synthesis
Leal-Junior and colleagues reported that pre-exercise light therapy can lower blood creatine kinase, a marker of muscle damage, compared with placebo (Leal-Junior 2010, PMID:20436237). That trial enrolled 9 participants and measured biochemical markers only; it did not measure blood flow, so it does not establish that the effect works through improved circulatory clearance.
Joint Health: Overcoming Avascular Tissue Challenges
Articular cartilage is avascular — it has no direct blood supply. Nutrients reach chondrocytes (cartilage cells) entirely through diffusion from the synovial fluid, which itself is produced by the synovial membrane's blood supply.
NO-mediated vasodilation in the synovial membrane and periarticular tissue enhances:
- Synovial fluid production and quality
- Nutrient diffusion gradients to cartilage
- Removal of inflammatory mediators from the joint space
- Reduced intra-articular pressure (from improved venous and lymphatic drainage)
This may explain why PBM improves joint function in osteoarthritis (Hegedus et al., 2009) despite light not directly reaching deep within the cartilage itself — the circulatory improvement in surrounding tissue supports cartilage nutrition indirectly.
Skin Health: The Glow Effect
The visible improvement in skin tone and "glow" that many users notice after PBM sessions is largely attributable to NO-mediated vasodilation in the dermal microvasculature.
Enhanced dermal blood flow delivers:
- More oxygen and nutrients to fibroblasts (supporting collagen synthesis)
- More amino acid substrates for protein synthesis
- Better clearance of metabolic waste and damaged proteins
- Improved thermoregulation (skin temperature homeostasis)
The immediate "glow" fades within hours, but with consistent treatment, the cumulative circulatory enhancement supports the structural skin improvements (collagen density, elasticity, reduced wrinkles) that develop over 4-12 weeks.
Brain: Cerebral Blood Flow
Cerebral blood flow (CBF) is tightly regulated to match the brain's enormous metabolic demands. NO is one of the primary regulators of cerebral vasodilation.
Transcranial PBM is proposed to release NO from mitochondria in cortical neurons and surrounding tissue, improving local cerebral blood flow. Salgado et al. (2015, Lasers in Medical Science, PMID:25277249) measured increased cerebral blood-flow velocity by transcranial Doppler in 25 healthy elderly women after four weeks of transcranial LED, consistent with NO-mediated vasodilation in cortical vessels. That trial used 627nm red light rather than the 810nm near-infrared wavelength usually cited for transcranial work, and it measured flow velocity, not cerebral oxygenation.
Enhanced cerebral blood flow supports:
- Oxygen and glucose delivery to neurons
- Clearance of metabolic waste (including amyloid-beta via the glymphatic system)
- Neurotransmitter substrate delivery
- Neural repair and plasticity
NO and Inflammation: A Nuanced Relationship
Nitric oxide has paradoxical effects on inflammation — it can be both anti-inflammatory and pro-inflammatory depending on the source, concentration, and tissue context.
| NO Source | Typical Level | Effect on Inflammation | Context |
|---|---|---|---|
| eNOS (endothelial) | Low (nM range) | Anti-inflammatory | Normal vascular homeostasis, vasodilation |
| nNOS (neuronal) | Low-moderate | Regulatory/neutral | Neural signaling, muscle regulation |
| iNOS (inducible) | High (μM range) | Pro-inflammatory | Immune activation, chronic inflammation, tissue damage |
| PBM photodissociation | Low-moderate | Anti-inflammatory | Controlled release restores homeostasis |
The controlled, localized NO release from PBM photodissociation differs fundamentally from the massive NO production by iNOS during chronic inflammation. PBM-derived NO:
- Is released in physiological (low-moderate) concentrations, not inflammatory (high) concentrations
- Acts locally in treated tissue, not systemically
- Simultaneously restores mitochondrial function (energy for inflammatory resolution)
- Promotes the switch from M1 (pro-inflammatory) to M2 (anti-inflammatory/repair) macrophage phenotype
Hamblin (2017, BBA Clinical) proposed that PBM's anti-inflammatory effect is partially mediated by this controlled NO release — providing enough NO for vasodilation and anti-inflammatory signaling without reaching the damaging concentrations associated with iNOS-driven inflammation.
Timing and Duration of NO-Mediated Effects
| Phase | Timing | Effect |
|---|---|---|
| Immediate (during treatment) | 0-15 min | NO photodissociation begins within seconds. CCO activity increases. Initial vasodilation starts |
| Peak vasodilation | 15-30 min post-treatment | Blood flow increase peaks. The only human measurement cited on this page (Samoilova 2008, polychromatic visible light) peaked at +45% around 20 min. Skin warmth and flushing may be visible |
| Sustained phase | 30-60 min post-treatment | Blood flow gradually returns toward baseline. Tissue oxygenation remains elevated |
| Secondary signaling | 1-6 hours post-treatment | NO-activated gene expression changes. Angiogenic factors upregulated. Anti-inflammatory pathways activated |
| Cumulative adaptation | Weeks of consistent treatment | Improved baseline vascular function. Enhanced eNOS expression. New capillary formation (angiogenesis) |
This timeline explains why consistent daily treatment produces benefits beyond what individual sessions can achieve. The cumulative effect includes structural vascular adaptations — new blood vessel formation and improved eNOS expression — that create lasting circulatory improvements.
Synergy: Combining PBM with NO-Supporting Strategies
Because PBM releases stored NO (from mitochondrial CCO) rather than producing new NO, combining it with strategies that increase NO synthesis may enhance the total NO-mediated benefit.
| Strategy | Mechanism | Synergy with PBM |
|---|---|---|
| Exercise | Shear stress activates eNOS | PBM releases stored NO; exercise produces new NO. Complementary pathways |
| Dietary nitrates (beets, leafy greens) | Nitrate→nitrite→NO conversion | Increases NO substrate pool. PBM adds mitochondrial NO release |
| L-arginine/L-citrulline supplementation | Substrate for NOS enzymes | More substrate = more eNOS production. PBM adds photodissociation |
| Breathing exercises (nasal breathing) | Paranasal sinuses produce NO | Nasal breathing delivers sinus NO to lungs. PBM adds systemic tissue NO |
| Cold exposure (cold plunge) | Vasoconstriction followed by rebound vasodilation | PBM before cold exposure may prime vascular reactivity. Sequence matters |
Optimal PBM + Exercise Timing
For athletes and active individuals, the timing of PBM relative to exercise can optimize NO-mediated benefits:
- Pre-exercise PBM (10-30 min before): NO release pre-dilates muscle vasculature, improving oxygen delivery during exercise. May enhance warm-up efficiency and initial performance
- Post-exercise PBM (within 30 min): NO-mediated vasodilation enhances metabolic waste clearance during the critical post-exercise recovery window. Combined with exercise-induced eNOS activation for sustained circulatory benefit
- Both pre and post: Maximum benefit for competitive athletes. Pre-exercise for performance, post-exercise for recovery
Safety: Why PBM-Derived NO Is Safe
Unlike pharmaceutical NO donors (nitroglycerin, nitroprusside), PBM-derived NO release has an inherently safe dose-response profile:
- Self-limiting: Only the NO bound to CCO is released. Once all bound NO is photodissociated, no additional NO is generated. The amount released is proportional to the amount stored in mitochondria — typically low-physiological concentrations
- Localized: NO has a half-life of ~5 seconds in tissue. Effects are primarily local to the treated area, not systemic
- No tolerance development: Pharmaceutical NO donors (nitroglycerin) cause tolerance with repeated use. PBM-derived NO release does not appear to develop tolerance, as the mechanism is physical (photodissociation) rather than pharmacological
- No dangerous interactions: No reported adverse interactions between PBM and cardiovascular medications, blood thinners, or other NO-pathway drugs at standard therapeutic doses
However, individuals on vasodilating medications (nitroglycerin, PDE5 inhibitors like sildenafil) should be aware that PBM adds an additional vasodilatory stimulus. While no adverse interactions have been reported, discussing PBM use with a healthcare provider is prudent for anyone on cardiovascular medications.
The Cardiovascular Potential
Emerging research suggests that whole-body PBM may have meaningful cardiovascular benefits through sustained NO-mediated vascular conditioning:
- Improved endothelial function (the endothelium is the tissue that produces eNOS)
- Reduced arterial stiffness through improved vascular smooth muscle relaxation
- Enhanced microcirculation in peripheral tissues
- Potential blood pressure modulation through sustained vasodilatory training
Sene-Fiorese et al. (2015, PMID:26220050) found that 808nm phototherapy added to aerobic plus resistance training produced greater reductions in fat mass and insulin resistance (HOMA-IR) than exercise alone in obese women; that trial measured no vascular or endothelial outcome. The cardiovascular effects listed above are an extrapolation from the vasodilation mechanism, not a measured result. PBM is not a cardiovascular treatment, and no study cited on this page has tested whether its circulatory effects translate into cardiovascular outcomes.
The Hale RLPRO series delivers both red and near-infrared wavelengths that trigger NO photodissociation from cytochrome c oxidase. Full-body coverage ensures NO-mediated vasodilation occurs across large tissue volumes, maximizing the circulatory benefit of each treatment session. Combined with the ATP enhancement from restored Complex IV function, each session provides the dual benefit that makes photobiomodulation a unique therapeutic modality.
Frequently Asked Questions
How does red light therapy affect nitric oxide?
Red and near-infrared light releases nitric oxide (NO) from two sources: it dissociates NO from cytochrome c oxidase in mitochondria (where NO acts as an inhibitor), and it triggers NO release from intracellular stores including nitrosothiols and nitrosylated hemoglobin. The released NO enters surrounding tissue where it acts as a potent vasodilator, increases blood flow, reduces inflammation, and serves as a signaling molecule for tissue repair and immune modulation.
Is the nitric oxide from red light therapy beneficial?
Yes. The photobiomodulation-induced NO release produces multiple beneficial effects: vasodilation improves blood flow and oxygen delivery to treated tissues, reduced platelet aggregation improves microcirculation, anti-inflammatory signaling modulates immune responses, and enhanced neural signaling supports nerve function. These NO-mediated effects complement the direct ATP-boosting mechanism and contribute significantly to the clinical benefits observed with red light therapy for pain, wound healing, and cardiovascular health.
Can red light therapy improve blood circulation?
Yes. Photobiomodulation improves blood circulation through nitric oxide-mediated vasodilation of arterioles and capillaries, enhanced endothelial function, reduced blood viscosity, and stimulation of angiogenesis (new blood vessel formation) in chronically treated areas. Clinical studies demonstrate measurably increased peripheral blood flow following red light therapy sessions. This improved circulation is one of the key mechanisms by which the therapy accelerates wound healing, reduces edema, and enhances tissue oxygenation.
Key Takeaways
- Nitric oxide is a master signaling molecule controlling vasodilation, immune function, neurotransmission, and mitochondrial regulation
- PBM releases NO from cytochrome c oxidase through photodissociation — a mechanism unique to light therapy
- This produces a dual benefit: restored mitochondrial ATP production and improved local circulation
- The only human blood-flow measurement cited here (Samoilova 2008, polychromatic visible light) found skin blood flow up 32% at 2 minutes and 45% at 20 minutes, returning to baseline by 90 minutes; the other studies are animal models or measure something other than blood flow
- NO-mediated circulation improvements benefit wound healing, muscle recovery, joint nutrition, skin health, and brain function
- PBM-derived NO is anti-inflammatory at physiological concentrations, distinct from the pro-inflammatory NO produced by iNOS in chronic inflammation
- Combining PBM with exercise, dietary nitrates, and other NO-supporting strategies may enhance the total circulatory benefit
- The effect is self-limiting, localized, and safe — no tolerance development or dangerous interactions reported
